We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are re-engineering the way highly complex vaccines are made through the XpressCF cell-free protein synthesis platform.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$1.06B
▼ -65.2% YoY
Op. Margin
–
ROIC
-31.30%
▼ -4.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$894M
▼ -40.9% YoY
Op. Cash Flow (TTM)
-$881M
▼ -44.8% YoY
Net Debt
-$1.37B
Net Cash Position
Cash & Equiv.
$1.49B
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with PCVX
Held by ETFs
PCVX is in 86 US ETFs. The largest of them, with PCVX's weight in each:
Vaxcyte (PCVX) in two numbers
Questions about Vaxcyte
Does Vaxcyte (PCVX) pay a dividend?
No. Vaxcyte (PCVX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 3 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in PCVX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PCVX
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.